¼¼°èÀÇ ¿Ü¿ë¾à CDMO ½ÃÀå
Topical Drugs CDMO
»óǰÄÚµå : 1777627
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 370 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¿Ü¿ë¾à CDMO ½ÃÀåÀº 2030³â±îÁö 797¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 449¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¿Ü¿ë¾à CDMO ½ÃÀåÀº 2024-2030³â¿¡ CAGR 10.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 797¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¹Ý°íÇü Á¦Á¦´Â CAGR 8.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 308¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾×ü Á¦Á¦ ÀǾàǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 12.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 122¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¿Ü¿ë¾à CDMO ½ÃÀåÀº 2024³â¿¡ 122¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 160¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 13.4%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 7.4%¿Í 8.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 7.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿Ü¿ë¾à CDMO ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

CDMO´Â ÀǾàǰ °³¹ß ȯ°æ¿¡ ¾î¶² Çõ¸íÀ» °¡Á®¿À°í Àִ°¡?

CDMO(ÀǾàǰ °³¹ß ¹× Á¦Á¶ ¼öʱâ°ü)´Â Á¦Á¦ °³¹ßºÎÅÍ »ó¾÷Àû ±Ô¸ðÀÇ »ý»ê±îÁö ¿£µå-Åõ-¿£µå ¼­ºñ½º¸¦ Á¦°øÇÔÀ¸·Î½á ¼ºÀåÇÏ´Â ¿Ü¿ëÁ¦ ½ÃÀå¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÇǺΰú, ÅëÁõ °ü¸®, °æÇǾ๰Àü´Þ¿¡ ´ëÇÑ ¿Ü¿ëÁ¦ ¼ö¿ä Áõ°¡´Â Á©, Å©¸², ·Î¼Ç, ¿¬°í, ÆÐÄ¡ µî ¿Ü¿ëÁ¦ Àü¹® CDMOÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦ ¹× »õ·Î¿î ¾à¹°Àü´Þ ±â¼úÀÇ ºÎ»óÀ¸·Î ½ÃÀå ÀáÀç·ÂÀÌ ´õ¿í Ä¿Áö°í ÀÖÀ¸¸ç, Á¦¾à»çµéÀº ºñ¿ë Àý°¨°ú ½ÃÀå Ãâ½Ã ½Ã°£ ´ÜÃàÀ» À§ÇØ CDMO¿¡ ¿¬±¸°³¹ß ¹× Á¦Á¶¸¦ À§Å¹Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª º¹ÀâÇÑ ±ÔÁ¦, °ø±Þ¸Á ¹®Á¦, Ư¼ö ¿Ü¿ëÁ¦Á¦ÀÇ ³ôÀº ºñ¿ë µîÀº ¿©ÀüÈ÷ Å« °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¦¾à±â¾÷ÀÌ È¿À²¼º°ú À¯¿¬¼ºÀ» ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, CDMO´Â ¿Ü¿ëÁ¦ ºÐ¾ß¿¡¼­ ¾î¶»°Ô Çõ½ÅÀ» °è¼Ó ÃßÁøÇÒ ¼ö Àִ°¡?

¾î¶² ±â¼ú Çõ½ÅÀÌ ¿Ü¿ëÁ¦ CDMOÀÇ ´É·ÂÀ» ¹ßÀü½Ã۰í Àִ°¡?

¸¶ÀÌÅ©·ÎÀÎĸ½¶·¹ÀÌ¼Ç ¹× ³ª³ëÀÔÀÚ ±â¹Ý ¾à¹°Àü´ÞÀÇ ¹ßÀüÀ¸·Î ¿Ü¿ëÁ¦ÀÇ È¿´É°ú ¾ÈÁ¤¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ¸ðµ¨¸µÀº Á¦Á¦ °³¹ßÀ» ÃÖÀûÈ­Çϰí Ãʱ⠴ܰèÀÇ ½ÃÇè¿¡ ¼Ò¿äµÇ´Â ½Ã°£°ú ºñ¿ëÀ» Àý°¨Çϰí ÀÖ½À´Ï´Ù. °æÇÇ¿ë ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡´Â ºñħ½ÀÀû ¾à¹°Àü´ÞÀÇ ´ë¾ÈÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, CDMOÀÇ ´É·ÂÀ» ±âÁ¸ÀÇ Å©¸²À̳ª ¿¬°í ÀÌ»óÀ¸·Î È®ÀåÇϰí ÀÖ½À´Ï´Ù. ¿¬¼Ó ó¸® ¹× ½Ç½Ã°£ ǰÁú°ü¸® ºÐ¼®À» Æ÷ÇÔÇÑ ½º¸¶Æ® Á¦Á¶ ±â¼úÀº »ý»ê È¿À²À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿ÀÀǾàǰÀÇ ¹ßÀüÀ¸·Î ÆéƼµå¿Í ´Ü¹éÁúÀ» ¿Ü¿ëÁ¦¿¡ Á¢¸ñÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ ¸¸¼º ÇǺΠÁúȯ°ú ÅëÁõ °ü¸®¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¿Ü¿ëÁ¦ CDMO¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ÇǺΠÁúȯÀÇ À¯º´·ü Áõ°¡, ºñħ½ÀÀû ¾à¹° Åõ¿©¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, °æÇÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î Àü¹® CDMOÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀº ÀÎÇÁ¶ó ºñ¿ëÀ» Àý°¨ÇÏ°í ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀ» ±Øº¹Çϱâ À§ÇØ °³¹ß ¹× Á¦Á¶ ¾Æ¿ô¼Ò½ÌÀ» Á¡Á¡ ´õ ¸¹ÀÌ ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿Í ¸ÂÃãÇü ±¹¼Ò Ä¡·áÀÇ ÃâÇöÀº À¯¿¬ÇÑ CDMO ÆÄÆ®³Ê½Ê¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¿Ü¿ëÁ¦ CDMO ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¾à¹°Àü´Þ ±â¼úÀÇ ¹ßÀü, ÀǾàǰ Á¦Á¶ ¾Æ¿ô¼Ò½Ì Áõ°¡, ÇǺΰú Ä¡·á ¹× °æÇÇ ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¹ÙÀÌ¿ÀÀǾàǰÀÇ CDMO ¿ª·® È®´ë°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è Á¦¾à¾÷°è°¡ ¼öŹÁ¦Á¶À» °è¼Ó ¹Þ¾ÆµéÀ̰í ÀÖ´Â °¡¿îµ¥, ¿Ü¿ëÁ¦ Àü¹® CDMO´Â Á¦¾àȸ»ç¿¡ Çõ½ÅÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á Å« ¼ºÀåÀ» ÀÌ·ê ¼ö ÀÖÀ» °ÍÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¹Ý°íÇü Á¦Á¦, ¾×ü Á¦Á¦, °íÇü Á¦Á¦, °æÇÇ Èí¼öÇü Á¦Á¦), ¼­ºñ½º À¯Çü(¼öʰ³¹ß, ¼öŹÁ¦Á¶), ÃÖÁ¾»ç¿ëÀÚ(Á¦¾àȸ»ç, ¹ÙÀÌ¿À Á¦¾àȸ»ç, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Topical Drugs CDMO Market to Reach US$79.7 Billion by 2030

The global market for Topical Drugs CDMO estimated at US$44.9 Billion in the year 2024, is expected to reach US$79.7 Billion by 2030, growing at a CAGR of 10.0% over the analysis period 2024-2030. Semi-solid Formulations, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$30.8 Billion by the end of the analysis period. Growth in the Liquid Formulations Drugs segment is estimated at 12.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.2 Billion While China is Forecast to Grow at 13.4% CAGR

The Topical Drugs CDMO market in the U.S. is estimated at US$12.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.0 Billion by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.4% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Topical Drugs CDMO Market Trends & Drivers Summarized

How Are CDMOs Revolutionizing the Topical Drug Development Landscape?

Contract Development and Manufacturing Organizations (CDMOs) are playing a crucial role in the growing topical drug market by offering end-to-end services, from formulation development to commercial-scale production. The increasing demand for topical drugs in dermatology, pain management, and transdermal drug delivery is fueling the expansion of CDMOs specializing in gels, creams, lotions, ointments, and patches. The rise of biologics and novel drug delivery technologies is further enhancing market potential, with pharmaceutical companies outsourcing R&D and manufacturing to CDMOs to reduce costs and accelerate time-to-market. However, regulatory complexities, supply chain challenges, and the high costs of specialized topical formulations remain significant hurdles. As pharmaceutical firms prioritize efficiency and flexibility, how will CDMOs continue to drive innovation in the topical drug sector?

What Technological Innovations Are Advancing Topical Drug CDMO Capabilities?

Advancements in microencapsulation and nanoparticle-based drug delivery are improving the efficacy and stability of topical formulations. AI-driven predictive modeling is optimizing formulation development, reducing time and costs in early-stage trials. Transdermal microneedle patches are emerging as a non-invasive alternative for drug delivery, expanding CDMO capabilities beyond traditional creams and ointments. Smart manufacturing technologies, including continuous processing and real-time quality control analytics, are enhancing production efficiency. Additionally, biopharmaceutical advancements are allowing the incorporation of peptides and proteins into topical therapies, expanding treatment options for chronic skin diseases and pain management.

Why Is the Demand for Topical Drug CDMOs Increasing?

The rising prevalence of dermatological conditions, increasing preference for non-invasive drug administration, and growing demand for transdermal drug delivery systems are driving the need for specialized CDMOs. Pharmaceutical companies are increasingly outsourcing development and manufacturing to reduce infrastructure costs and navigate stringent regulatory requirements. The emergence of personalized medicine and customized topical therapies is further fueling demand for flexible CDMO partnerships.

What Factors Are Driving the Growth of the Topical Drug CDMO Market?

The market is growing due to advancements in drug delivery technologies, increasing outsourcing of pharmaceutical manufacturing, rising demand for dermatological and transdermal therapies, and expanding CDMO capabilities in biopharmaceutical formulations. As the global pharmaceutical landscape continues to embrace contract manufacturing, CDMOs specializing in topical drugs are poised for significant growth, offering innovative, cost-effective solutions for pharmaceutical companies.

SCOPE OF STUDY:

The report analyzes the Topical Drugs CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Semi-solid Formulations, Liquid Formulations Drugs, Solid Formulations, Transdermal Products); Service Type (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â